Iovance wins with Amtagvi and the ADC train chugs on

from BioSpace · host BioSpace

This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.

Episode metadata supplied by the publisher feed · Published Feb 21, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Iovance wins with Amtagvi and the ADC train chugs on

0:00 13:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 13 minutes long.

When was this BioSpace episode published?

This episode was published on February 21, 2024.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!